Thalidomide in induction treatment increases the very good partial response rate before and after high-dose therapy in previously untreated multiple myeloma

Henk M. Lokhorst, Ingo Schmidt-Wolf, Pieter Sonneveldbronno Van Der Holt, Hans Martin, Rene Barge, Uta Bertsch, Jana Schlenzka, Gerard M.J. Bos, Sandra Croockewit, Sonja Zweegman, Iris Breitkreuz, Peter Joosten, Christof Scheid, Marinus Van Marwijk-Kooy, Hans Juergen Salwender, Marinus H.J. Van Oers, Ron Schaafsma, Ralph Naumann, Harm Sinnige, Igor BlauGregor Verhoef, Okke De Weerdt, Pierre Wijermans, Shulamiet Wittebol, Ulrich Duersen, Edo Vellenga, Hartmut Goldschmidt

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

In the prospective phase 3 HOVON-50/GMMG-HD3 trial, patients randomized to TAD (thalidomide, doxorubicin, dexamethasone) had a significantly higher response rate (at least PR) after induction compared with patients randomized to VAD (vincristine, adriamycin, dexamethasone, 72% vs. 54%, p
Original languageEnglish
Pages (from-to)124-127
Number of pages4
JournalHaematologica
Volume93
Issue number1
DOIs
Publication statusPublished - Jan 2008

Cite this

Lokhorst, H. M., Schmidt-Wolf, I., Van Der Holt, P. S., Martin, H., Barge, R., Bertsch, U., ... Goldschmidt, H. (2008). Thalidomide in induction treatment increases the very good partial response rate before and after high-dose therapy in previously untreated multiple myeloma. Haematologica, 93(1), 124-127. https://doi.org/10.3324/haematol.11644